Clinical Microbiology and Antimicrobial Chemotherapy. 2007; 9(1):48-56
Multicenter prospective non-comparative open-label clinical study to assess clinical and microbiological efficacy and safety of josamycin (16-memebered macrolide) in adults with non-severe community-acquired pneumonia (CAP) was performed. Patients who met all the inclusion/exclusion criteria were given 0.5 g of josamycin t.i.d (withor without food). A total of 88 ambulatory and hospitalized patients (mean age was 45.5±13.7 years) with non-severe CAP and associated low/medium risk for poor outcome were included. The mean duration of antimicrobial therapy was 7.8±1.4 days. Clinical efficacy of josamycin was reported in 92.8% of cases. Patients receiving josamycin experienced rapid resolution of clinical symptoms and defervescence. Microbiological cure rate (eradication and probable eradication) was 85.7%. Adverse events (gastrointestinal) possibly related to josamycin were reported in 8% of patients. All adverse events were mild and transient; the only 1 case of therapy discontinuation due to an adverse event was reported. Josamycin was well tolerated in 98.9% of patients.